Aminocaproic acid dosage and administration

Revision as of 04:48, 31 January 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Aminocaproic acid}} {{CMG}}; {{AE}} {{SS}} ==Dosage and Administration== An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Ora...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Aminocaproic acid
AMICAR® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Dosage and Administration

An identical dosage regimen may be followed by administering AMICAR Tablets or AMICAR Oral Solution as follows: For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliter of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliter of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.[1]

References

  1. "AMICAR (AMINOCAPROIC ACID) SOLUTION AMICAR (AMINOCAPROIC ACID) TABLET [CLOVER PHARMACEUTICALS CORP.]". Retrieved 31 January 2014.


Template:WikiDoc Sources